Obligate Oncolytic HSV Vector for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic herpes simplex viruses (oHSV) used in cancer therapy are often over-attenuated, limiting their potency and effectiveness, and systemic administration of immunotherapeutic agents like anti-PD1 or CTLA-4 antibodies is associated with side effects and limited administration frequency.
Innovation Solution
A modified HSV-1 oncolytic virus with a deleted genome between the UL56 and US1 promoters, allowing for the incorporation of immunostimulatory and immunotherapeutic agents such as IL-12, anti-PD1, and anti-CTLA-4, which enhances immune response and cytotoxicity against cancer cells while minimizing side effects through localized administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current oncolytic herpes simplex viruses (oHSV) are used in cancer therapy, then they can replicate in cancer cells with compromised innate immune responses, but they are over-attenuated which limits their potency and effectiveness
Solution Approach 1:
The patent modifies the viral genome by deleting specific genes (US3, US11, UL49.5) and adjusting gene expression parameters to optimize the balance between safety and potency. The deleted genes reduce attenuation while the modified expression levels of remaining genes enhance oncolytic activity without compromising safety
Solution Approach 2:
The patent creates a composite viral construct by combining multiple genetic elements with different functions - including immunostimulatory genes (IL-12, GM-CSF), immunotherapeutic genes (anti-PD1, anti-CTLA-4), and structural viral genes - into a single integrated genome that achieves both safety and potency simultaneously
2Reliability
If immunotherapeutic agents like anti-PD1 or CTLA-4 antibodies are administered systemically, then they can enhance immune response against cancer, but they are associated with side effects and limited administration frequency
Solution Approach 1:
The patent implements local delivery of immunotherapeutic agents by incorporating them into the viral genome for localized expression at the tumor site. This ensures high concentration of therapeutic agents where needed while minimizing systemic exposure and associated side effects
Solution Approach 2:
The oncolytic virus serves as an intermediary delivery vehicle that transports and expresses immunotherapeutic genes directly at the tumor site. The virus mediates localized gene expression, converting systemic therapy into localized therapy while maintaining efficacy
Data Source
AI summary
An obligate oHSV vector comprising modified viral DNA genome is provided. A recombinant oHSV-1 construct comprising the obligate oHSV vector and a heterologous nucleic acid sequence encoding an immunostimulatory and/or immunotherapeutic agent is also provided. Compositions comprising the recombinant oHSV-1 construct can be used for treating cancers.